The regulation and legalisation of medicinal cannabis is one of the hottest topics in the pharmaceutical industry. 

We have closely watched developments in a number of countries across the globe for many years, including in those jurisdictions where medicinal cannabis is more widely prescribed as well as those where the regulatory regime is more restrictive. 

We are proud to represent clients operating at the cutting edge of this rapidly-evolving industry, from animal nutraceuticals and cosmetics producers to medical device manufacturers developing novel delivery mechanisms for medical cannabis. 

We offer decades of market leading expertise advising on the challenges and opportunities faced by 'traditional' growth-stage pharmaceutical companies. This includes assisting on applications for licenses to operate (and related administrative matters), ensuring robust IP protection, raising capital (including those seeking venture capital financing and those raising funds on the public markets), mergers and acquisitions and other strategic transactions. 

Our global team offers multi-jurisdictional advice from local experts with in-depth industry knowledge to help our clients navigate the complex and evolving legal and regulatory landscape impacting this booming industry.  

As efficient and commercially-focused lawyers, we offer solutions to companies entering and expanding in the medicinal cannabis market. In April, the Federal Institute for Drugs and Medical Devices (BfArM) awarded our client advised Aphria Deutschland GmbH several lots for the cultivation, processing and delivery of cannabis for medical purposes. This procedure is seen as a blueprint for the liberalisation of the market for medicinal cannabis in Europe and a testament to our partnership with innovative companies. 

We can advise on:
 

Recent highlights of work

News & Events